Join the Alliance for Aging Research on Feb. 9  at 1PM ET for an important conversation about how the Centers for Medicare and Medicaid Services’ (CMS) draft coverage decision will set a dangerous precedent for rationing Medicare beneficiaries’ access to current and future FDA-approved Alzheimer’s drugs, as well as future treatments for other serious and life-threatening conditions approved under the FDA’s accelerated approval pathway.